Grifols (BME:GRF) Full Year 2023 Results
Key Financial Results
- Revenue: €6.59b (up 8.7% from FY 2022).
- Net income: €59.3m (down 72% from FY 2022).
- Profit margin: 0.9% (down from 3.4% in FY 2022). The decrease in margin was driven by higher expenses.
- EPS: €0.087 (down from €0.31 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Grifols EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 59%.
Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe.
Performance of the market in Spain.
The company's shares are up 5.0% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Grifols (2 are a bit unpleasant!) that you should be aware of before investing here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BME:GRF
Grifols
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Reasonable growth potential with proven track record.
